CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its third quarter 2017 investor update conference call and webcast at
8:30 a.m. Eastern Time on Thursday, November 2, 2017. Individuals
interested in participating in the call should dial (877) 643-7155 (U.S.
and Canada) or (914) 495-8552 (international) using conference ID number
1071726. To access the webcast, please visit the Investors section of
Ironwood's website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
The call will be available for replay via telephone starting November 2,
2017 at approximately 11:30 a.m. Eastern Time, running through 11:59
p.m. Eastern Time on November 9, 2017. To listen to the replay, dial
(855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 1071726. The archived webcast will be available on
Ironwood's website for 14 days beginning approximately one hour after
the call has completed.
About Ironwood Pharmaceuticals
(NASDAQ: IRWD) is a commercial biotechnology company focused on creating
medicines that make a difference for patients, building value for our
fellow shareholders, and empowering our passionate team. We are
commercializing two innovative primary care products: linaclotide, the
U.S. branded prescription market leader for adults with irritable bowel
syndrome with constipation (IBS‐C) or chronic idiopathic constipation
(CIC), and lesinurad, which is approved for the treatment of
hyperuricemia associated with gout in patients who have not achieved
target serum uric acid (sUA) levels with a medically appropriate daily
dose of a xanthine oxidase inhibitor (XOI) alone. We are also advancing
a pipeline of internally and externally generated innovative product
candidates in areas of significant unmet need, including uncontrolled
gastroesophageal reflux disease and vascular and fibrotic diseases.
Ironwood was founded in 1998 and is headquartered in Cambridge, Mass.
For more information, please visit www.ironwoodpharma.com
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171019005190/en/
Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
Director, Investor Relations and Corporate Communications
Source: Ironwood Pharmaceuticals, Inc.
News Provided by Acquire Media